Dr. Reddy’s Laboratories and Nasdaq-listed Vivus Inc. have entered into settlement agreement to resolve a long-pending patent litigation related to weight management capsule Qsymia.
The settlement permits the Hyderabad-based drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances. In the event of an early launch, Vivus will receive a royalty on sales of the generic version of the drug.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
